PreviousNext
  • Subscribe to HTA Quarterly

    Get at-a-glance updates on important HTA decisions. Each edition of the HTA Quarterly provides insight into the evolving perspectives and priorities for HTAs.

    Read More
  • Subscribe to Health Policy Weekly

    Recaps legislative and regulatory developments and healthcare reform news that impacts the healthcare industry.

    Read More

1 of 0 Items

  • ICD-10: A Top Worry on Providers' Minds

    The implementation of ICD-10 will introduce thousands of new codes into the healthcare process, putting a significant administrative burden on providers and their office staff. What key issues are weighing on the minds of these stakeholders when it comes to ICD-10? And how will that affect your strategy to prepare your products for the transition? We delved into the question and found some revealing answers. More

  • ICD-10 Readiness for Manufacturers

    The transition to ICD-10 poses many potential challenges for manufacturers. Our most current White Paper provides guidance to become business ready for ICD-10. Discover actionable strategies to offer providers the support programs and tools that will help your patients continue to quickly start, and remain, on therapy. More

  • Biosimilars in the US: Are We There Yet?

    January 7, 2015 marked a historical date for the US healthcare market when the Food and Drug Administration’s (FDA’s) first Oncology Drug Advisory Committee (ODAC) meeting for a biosimilar took place. The drug under review was Sandoz’s biosimilar to filgrastim, still known as EP2006. Dr. Fernandez-Lopez reviews the outcomes and learnings from the meeting and provide insight on what manufacturers need to consider in regard to biosimilars. More

  • Small Population, Huge Impact: Navigating European Market Access With an Orphan Disease Product

    Deriving its name from the belief that no manufacturer would care to adopt them, “orphan disease” molecule development was traditionally eschewed by companies for the chance to develop medicines in larger and more profitable markets. Due to the significant incentives available for rare conditions, more and more manufacturers are focusing on developing and marketing molecules for orphan conditions. This article will help you navigate the EMA for sucessful market access. More

  • Try Out the HTA Decision Map

    Xcenda's Decision Map makes it easy to stay informed on key HTA decisions from Australia, Canada, France, Germany, and the United Kingdom. More

  • HTA Quarterly Archive: Insights to Bridge Science and Policy

    Find articles from current and past issues of the HTA Quarterly, Xcenda's e-newsletter written specifically by and for health economics and market access professionals. More

  • Health Policy Weekly Archive

    Miss a recent issue? Get up to date with the latest regulatory and legislative happenings and news that impact stakeholders in the healthcare industry. More

Explore More Insights

We invite you to explore our library of articles, webcasts, white papers, and more.